UY25101A1 - Método para el tratamiento de la diabetes mellitus y las condiciones asociadas - Google Patents

Método para el tratamiento de la diabetes mellitus y las condiciones asociadas

Info

Publication number
UY25101A1
UY25101A1 UY25101A UY25101A UY25101A1 UY 25101 A1 UY25101 A1 UY 25101A1 UY 25101 A UY25101 A UY 25101A UY 25101 A UY25101 A UY 25101A UY 25101 A1 UY25101 A1 UY 25101A1
Authority
UY
Uruguay
Prior art keywords
diabetes mellitus
insulin
mammal
alpha
treatment
Prior art date
Application number
UY25101A
Other languages
English (en)
Inventor
Stephen Smith
Robin Buckingham
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of UY25101A1 publication Critical patent/UY25101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

Un método para el tratamiento de la diabetes mellitus y las condiciones asociadas con la diabetes mellitus en un mamífero, cuyo método comprende administrar una cantidad eficaz no tóxica y farmacéuticamente aceptable de un sensibilizador a insulina, un secretagogo de insulina y un agente antihiperglucemico inhibidor de alfa-glucosidasa, a un mamifero que necesita del mismo. En donde el secretagogo de insulina se selecciona entre glibenclamida, glipizida, glidlazida, glimepirida, clorpropamida, glibornurida, gliquidona, glisentida, glisolamida, glisoxepida, glicopiamida, glicidamida o repaglinida; el agente antihiperglucémico inhibidor de alfa-glucosidasa es acarbosa, emiglitato y miglitol; y el sensibilizador a insulina es 5-[4-[2-(N-metil-N-(2-piridil)amino)etoxi]-bencil]tiazolidin-2,4-diona.
UY25101A 1997-07-18 1998-07-17 Método para el tratamiento de la diabetes mellitus y las condiciones asociadas UY25101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB9715298A GB9715298D0 (en) 1997-07-18 1997-07-18 Novel method of treatment

Publications (1)

Publication Number Publication Date
UY25101A1 true UY25101A1 (es) 2000-12-29

Family

ID=10816170

Family Applications (1)

Application Number Title Priority Date Filing Date
UY25101A UY25101A1 (es) 1997-07-18 1998-07-17 Método para el tratamiento de la diabetes mellitus y las condiciones asociadas

Country Status (27)

Country Link
EP (1) EP1001784A1 (es)
JP (1) JP2001510160A (es)
KR (1) KR20010021952A (es)
CN (1) CN1263467A (es)
AP (1) AP2000001735A0 (es)
AR (2) AR016350A1 (es)
AU (1) AU8449098A (es)
BG (1) BG104062A (es)
BR (1) BR9810292A (es)
CA (1) CA2297133A1 (es)
CO (1) CO4940489A1 (es)
DZ (1) DZ2563A1 (es)
EA (1) EA200000140A1 (es)
GB (1) GB9715298D0 (es)
HU (1) HUP0003626A3 (es)
ID (1) ID23804A (es)
IL (1) IL133907A0 (es)
MA (1) MA24608A1 (es)
NO (1) NO20000230D0 (es)
OA (1) OA11312A (es)
PE (1) PE99499A1 (es)
PL (1) PL338140A1 (es)
SK (1) SK612000A3 (es)
TR (1) TR200000133T2 (es)
UY (1) UY25101A1 (es)
WO (1) WO1999003478A1 (es)
ZA (1) ZA986364B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2291210T3 (es) * 1999-06-21 2008-03-01 Eli Lilly And Company Uso sinergistico de tiazolidindionas con peptido-1 tipo glucagona y sus agonistas para tratar la diabetes no insulina-dependiente.
BRPI0107715B8 (pt) * 2000-01-21 2021-05-25 Novartis Ag produto farmacêutico compreendendo um inibidor de dipeptidilpeptidase-iv e metformina, bem como usos do dito produto farmacêutico e do inibidor de dipeptidilpeptidase-iv
EP1295609A4 (en) * 2000-02-24 2004-11-03 Takeda Chemical Industries Ltd DRUGS CONTAINING COMBINED ACTIVE INGREDIENTS
JP4917712B2 (ja) * 2000-02-24 2012-04-18 武田薬品工業株式会社 併用医薬
JP4633329B2 (ja) 2001-01-12 2011-02-16 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド スペーストドラッグデリバリーシステム
FR2832930A1 (fr) * 2001-12-03 2003-06-06 Lipha Composition pharmaceutique comprenant un inhibiteur d'alpha-glucosidase et un derive de thiazolidinedione et son utilisation pour la preparation de medicaments destines a traiter le diabete
NZ546337A (en) 2003-10-31 2009-03-31 Takeda Pharmaceutical Solid preparation comprising an insulin sensitizer such as pioglitazone hydrochloride, an insulin secretagogue such as glimepiride and a polyoxyethylene sorbitan fatty acid ester such as Polysorbate 80
CN101103993B (zh) * 2006-07-14 2011-03-30 北京华安佛医药研究中心有限公司 降糖药物组合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2101866T3 (es) * 1991-08-26 1997-07-16 Upjohn Co Producto alimentario liquido que contiene acido 3-guanidinopropionico.
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TWI238064B (en) * 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes

Also Published As

Publication number Publication date
PL338140A1 (en) 2000-09-25
SK612000A3 (en) 2000-07-11
ZA986364B (en) 2000-01-17
CN1263467A (zh) 2000-08-16
NO20000230L (no) 2000-01-17
AR016350A1 (es) 2001-07-04
GB9715298D0 (en) 1997-09-24
WO1999003478A1 (en) 1999-01-28
AR019724A2 (es) 2002-03-13
HUP0003626A3 (en) 2001-12-28
BG104062A (en) 2000-11-30
DZ2563A1 (fr) 2003-02-15
TR200000133T2 (tr) 2000-09-21
CO4940489A1 (es) 2000-07-24
ID23804A (id) 2000-05-11
EP1001784A1 (en) 2000-05-24
AU8449098A (en) 1999-02-10
MA24608A1 (fr) 1999-04-01
NO20000230D0 (no) 2000-01-17
IL133907A0 (en) 2001-04-30
PE99499A1 (es) 1999-12-18
KR20010021952A (ko) 2001-03-15
BR9810292A (pt) 2000-09-19
CA2297133A1 (en) 1999-01-28
OA11312A (en) 2003-10-24
JP2001510160A (ja) 2001-07-31
HUP0003626A2 (hu) 2001-05-28
AP2000001735A0 (en) 2000-01-16
EA200000140A1 (ru) 2000-06-26

Similar Documents

Publication Publication Date Title
MY129897A (en) Use of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2, 4-dione and metformin for the treatment of diabetes mellitus
AR057970A2 (es) Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus y procedimientos para preprar dichas composiciones
UY25101A1 (es) Método para el tratamiento de la diabetes mellitus y las condiciones asociadas
UY25799A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina y otro agente antidiabético.
PE99599A1 (es) Composicion farmaceutica para el tratamiento de la diabetes
UY24893A1 (es) Combinaciones para diabetes de sulfonilurea glitazona
EP1593379A3 (en) Uses of PPAR-gamma agonists in neutrophil-induced diseases
NO20083276L (no) Behandling av diabetes med tiazolidindion og sulfonylurea
AR012997A1 (es) Uso de 5-[4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidin-2,4- diona e insulina para la preparacion de medicamentos, y composicionfarmaceutica que los contiene.
NZ513922A (en) Composition comprising 5-Ä4-Ä2-(N-methyl-N-2-pyridyl)-amino)ethoxy!benzyl!thiazolidine-2-4-dione
UY25051A1 (es) Composiciones para el tratamiento de diabetes mellitus
AR016768A1 (es) COMPOSICIoN FARMACÉUTICA DE 5-(4- (2-(N-METIL-N-(2-PIRIDIL) AMINO)ETOXI)BENCIL)TIAZOLIDIN-2-4-DIONA Y UN SECRETAGOGO DE INSULINA Y USO DE LA MISMA PARA PREPARACIoN DE MEDICAMENTOS
UY26112A1 (es) Dihidrato de hidrocloruro de 5- [4-[2-(n-metil-n-(2-piridil)amino)etoxi]bencil]tiazolidina-2,4-diona
AR104503A2 (es) Compuestos heterocíclicos de ácido borónico
NO20075507L (no) Tiazolidindionderivater og deres anvendelse som antidiabetiske midler
EA200300005A1 (ru) Соль тиазолидиндиона для лечения сахарного диабета
DK1315724T3 (da) Thiazolidindionderivat og dets anvendelse som antidiabetikum
RU2021105658A (ru) Способы отсрочки возникновения диабета 2 типа и замедления прогрессии, и лечения диабета 2 типа
ECSP982535A (es) Nuevo metodo de tratamiento (i)
ECSP982593A (es) Nuevo metodo de tratamiento vi
TH36758A (th) กรรมวิธีในการรักษาโรคเบาหวานด้วยไธอะโซลิดีนไดโอนและเมทฟอร์มิน
ECSP982592A (es) Nuevo metodo de tratamiento v

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20121207